Press "Enter" to skip to content

Balversa (erdafitinib) for the Treatment of Urothelial Carcinoma, USA – Drug Development Technology

admin 0

Balversa (erdafitinib) for the Treatment of Urothelial Carcinoma, USA  Drug Development Technology

Balversa™ is the first fibroblast growth factor receptor kinase inhibitor approved for the treatment of locally advanced or metastatic urothelial carcinoma.

“bladder cancer” – Google News

(Visited 2 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *